Pfizer Inc. (NYSE:PFE) Stake Boosted by Intech Investment Management LLC

Intech Investment Management LLC increased its holdings in Pfizer Inc. (NYSE:PFE) by 61.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 509,488 shares of the biopharmaceutical company’s stock after buying an additional 193,471 shares during the quarter. Intech Investment Management LLC’s holdings in Pfizer were worth $14,668,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Carr Financial Group Corp grew its holdings in Pfizer by 3.3% in the 3rd quarter. Carr Financial Group Corp now owns 11,012 shares of the biopharmaceutical company’s stock worth $344,000 after buying an additional 355 shares in the last quarter. Advisor OS LLC lifted its position in Pfizer by 1.0% in the fourth quarter. Advisor OS LLC now owns 35,202 shares of the biopharmaceutical company’s stock worth $1,013,000 after purchasing an additional 365 shares during the period. Safeguard Investment Advisory Group LLC lifted its position in Pfizer by 3.9% in the fourth quarter. Safeguard Investment Advisory Group LLC now owns 9,987 shares of the biopharmaceutical company’s stock worth $288,000 after purchasing an additional 371 shares during the period. Cairn Investment Group Inc. lifted its position in Pfizer by 5.4% in the third quarter. Cairn Investment Group Inc. now owns 7,323 shares of the biopharmaceutical company’s stock worth $243,000 after purchasing an additional 372 shares during the period. Finally, Monetary Management Group Inc. lifted its position in Pfizer by 1.0% in the third quarter. Monetary Management Group Inc. now owns 38,651 shares of the biopharmaceutical company’s stock worth $1,282,000 after purchasing an additional 375 shares during the period. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Up 0.7 %

Shares of PFE traded up $0.19 during mid-day trading on Friday, reaching $28.88. The company’s stock had a trading volume of 22,589,127 shares, compared to its average volume of 44,974,800. The business has a fifty day moving average of $27.27 and a 200 day moving average of $27.94. The company has a market cap of $163.65 billion, a price-to-earnings ratio of -481.25, a price-to-earnings-growth ratio of 1.13 and a beta of 0.63. Pfizer Inc. has a 1 year low of $25.20 and a 1 year high of $40.37. The company has a quick ratio of 0.78, a current ratio of 1.05 and a debt-to-equity ratio of 0.66.

Pfizer (NYSE:PFE) last released its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.56 by $0.26. The company had revenue of $14.88 billion during the quarter, compared to analyst estimates of $13.87 billion. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The company’s revenue for the quarter was down 19.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.23 earnings per share. As a group, analysts forecast that Pfizer Inc. will post 2.38 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be issued a $0.42 dividend. The ex-dividend date is Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.82%. Pfizer’s payout ratio is currently -2,799.53%.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on PFE shares. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research report on Monday, April 15th. Guggenheim started coverage on Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price for the company. Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Morgan Stanley upped their target price on Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 2nd. Finally, BMO Capital Markets reiterated an “outperform” rating and set a $36.00 price objective (up previously from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Ten research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Pfizer currently has a consensus rating of “Hold” and a consensus target price of $35.86.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.